AU
UK
CA
NZ
IND
US
Last update at 2026-06-05T20:00:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
3 ASX Stocks Estimated To Be Trading At A 10.1% To 41.2% Discount
Thu 14 May 26, 07:34 PMASX Stocks Trading At An Estimated Discount Of Up To 45.8% Below Intrinsic Value
Wed 13 May 26, 07:34 PMASX Stocks That Could Be Trading Below Their Estimated Value
Thu 30 Apr 26, 07:34 PM3 ASX Stocks Estimated To Be Undervalued By Up To 48.5%
Wed 22 Apr 26, 07:34 PMASX Stocks That May Be Trading Up To 46.2% Below Intrinsic Value Estimates
Thu 26 Mar 26, 07:35 PMASX Penny Stocks To Watch With Market Caps Over A$300M
Sun 18 Jan 26, 08:02 PMASX Penny Stocks Spotlight: Havilah Resources And Two More To Consider
Fri 05 Dec 25, 03:05 AM3 ASX Penny Stocks With Market Caps Larger Than A$90M
Thu 06 Nov 25, 08:02 PMASX Penny Stocks Spotlight Aeris Resources And Two More
Mon 29 Sep 25, 03:05 AM| Breakdown | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
| Income before tax | 60485.00M | 32298.00M | 28324.00M | 18032.00M | 22443.00M |
| Minority interest | - | - | - | - | 0.00000M |
| Net income | 45073.00M | 23568.00M | 19149.00M | 19498.00M | 18795.00M |
| Selling general administrative | 46466.00M | 62081.00M | 54559.00M | 50129.00M | 707.00M |
| Selling and marketing expenses | 59465.00M | - | - | - | - |
| Gross profit | 202972.00M | 113840.00M | 103077.00M | 94009.00M | 83430.00M |
| Reconciled depreciation | 12502.00M | 11824.00M | 12796.00M | 12472.00M | 12190.00M |
| Ebit | 96282.00M | 40818.00M | 36062.00M | 37055.00M | 11416.00M |
| Ebitda | 108784.00M | 52642.00M | 48858.00M | 49527.00M | 23606.00M |
| Depreciation and amortization | 12502.00M | 11824.00M | 12796.00M | 12472.00M | 12190.00M |
| Non operating income net other | - | - | - | - | 0.00000M |
| Operating income | 96282.00M | 40818.00M | 36062.00M | 37055.00M | 20888.00M |
| Other operating expenses | 160522.00M | 177353.00M | 156763.00M | 141840.00M | 132963.00M |
| Interest expense | 1428.00M | 958.00M | 970.00M | 983.00M | 1163.00M |
| Tax provision | 15412.00M | 8730.00M | 9175.00M | -1466.00000M | 3648.00M |
| Interest income | 1058.00M | 3077.00M | 1653.00M | 2034.00M | 1555.00M |
| Net interest income | -1428.00000M | 2119.00M | 1653.00M | -90.00000M | -119.00000M |
| Extraordinary items | - | 44.00M | 313.00M | 41.00M | -3.00000M |
| Non recurring | - | - | - | - | 0.00000M |
| Other items | - | - | - | - | 0.00000M |
| Income tax expense | 15412.00M | 8730.00M | 9175.00M | -1466.00000M | 3648.00M |
| Total revenue | 245879.00M | 214391.00M | 189722.00M | 174600.00M | 153851.00M |
| Total operating expenses | 117615.00M | 76802.00M | 70118.00M | 61249.00M | 62542.00M |
| Cost of revenue | 42907.00M | 100551.00M | 86645.00M | 80591.00M | 70421.00M |
| Total other income expense net | -35797.00000M | -8520.00000M | -7738.00000M | -19023.00000M | 438.00M |
| Discontinued operations | - | - | - | - | 0.00000M |
| Net income from continuing ops | 45073.00M | 23568.00M | 19149.00M | 19498.00M | 18795.00M |
| Net income applicable to common shares | 45073.00M | 23568.00M | 19149.00M | 19498.00M | 18795.00M |
| Preferred stock and other adjustments | - | - | - | - | 0.00000M |
| Breakdown | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
| Total assets | 322851.00M | 296654.00M | 265491.00M | 232241.00M | 225427.00M |
| Intangible assets | 30724.00M | 27246.00M | 35648.00M | 27659.00M | 44367.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | 15120.00M | 13902.00M | 14509.00M | 5755.00M | 12536.00M |
| Total liab | 89990.00M | 106127.00M | 90510.00M | 77253.00M | 85230.00M |
| Total stockholder equity | 232861.00M | 190527.00M | 174981.00M | 154988.00M | 140197.00M |
| Deferred long term liab | - | - | - | - | 0.00000M |
| Other current liab | 48862.00M | 41595.00M | 33514.00M | 39361.00M | 27415.00M |
| Common stock | 833.00M | 832.00M | 832.00M | 831.00M | 830.00M |
| Capital stock | 833.00M | 832.00M | 832.00M | 831.00M | 830.00M |
| Retained earnings | 215593.00M | 175712.00M | 157934.00M | 144247.00M | 128646.00M |
| Other liab | - | 2539.00M | 2739.00M | 3135.00M | 3530.00M |
| Good will | 5474.00M | 4418.00M | 4568.00M | 3994.00M | 3902.00M |
| Other assets | 7124.00M | 13729.00M | 11582.00M | 14795.00M | 5227.00M |
| Cash | 5779.00M | 14852.00M | 14829.00M | 2053.00M | 2228.00M |
| Cash and equivalents | 2928.00M | 75.00M | 316.00M | 118.00M | 111.00M |
| Total current liabilities | 85721.00M | 97842.00M | 81472.00M | 72814.00M | 59700.00M |
| Current deferred revenue | 1981.00M | 2576.00M | 2033.00M | 1910.00M | 1351.00M |
| Net debt | 7693.00M | 18993.00M | 15479.00M | 20049.00M | 36153.00M |
| Short term debt | 12194.00M | 28099.00M | 24009.00M | 20798.00M | 16381.00M |
| Short long term debt | 12194.00M | 28099.00M | 24009.00M | 20315.00M | 16324.00M |
| Short long term debt total | 13472.00M | 33845.00M | 30308.00M | 22102.00M | 38381.00M |
| Other stockholder equity | 15169.00M | 12924.00M | 14889.00M | 9910.00M | 10721.00M |
| Property plant equipment | 66294.00M | 62169.00M | 57111.00M | 52332.00M | 54088.00M |
| Total current assets | 204255.00M | 181106.00M | 148249.00M | 130370.00M | 114501.00M |
| Long term investments | 6089.00M | 7986.00M | 8333.00M | 3091.00M | 3342.00M |
| Net tangible assets | - | 158863.00M | 134765.00M | 123335.00M | 91928.00M |
| Short term investments | 60969.00M | 29513.00M | 19744.00M | 23687.00M | 22529.00M |
| Net receivables | 72485.00M | 70049.00M | 52386.00M | 61754.00M | 43269.00M |
| Long term debt | 0.00000M | 5746.00M | 6299.00M | 0.00000M | 21448.00M |
| Inventory | 48670.00M | 50884.00M | 45412.00M | 35066.00M | 33579.00M |
| Accounts payable | 22684.00M | 25572.00M | 21916.00M | 10745.00M | 14553.00M |
| Total permanent equity | - | - | - | - | 0.00000M |
| Noncontrolling interest in consolidated entity | - | - | - | - | 0.00000M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | 0.00000M |
| Accumulated other comprehensive income | 1266.00M | 1059.00M | 1326.00M | 2421.00M | 0.00000M |
| Additional paid in capital | - | - | - | - | 0.00000M |
| Common stock total equity | - | - | 832.00M | 831.00M | 830.00M |
| Preferred stock total equity | - | - | - | - | 0.00000M |
| Retained earnings total equity | - | - | - | - | 0.00000M |
| Treasury stock | - | - | -1967.00000M | -1006.00000M | -535.00000M |
| Accumulated amortization | - | - | - | - | 0.00000M |
| Non currrent assets other | 12715.00M | 948.00M | 952.00M | 2581.00M | 1059.00M |
| Deferred long term asset charges | - | - | - | - | 0.00000M |
| Non current assets total | 118596.00M | 115548.00M | 117242.00M | 101871.00M | 110926.00M |
| Capital lease obligations | 1278.00M | 2963.00M | 3363.00M | 1787.00M | 609.00M |
| Long term debt total | 1278.00M | 5746.00M | 6299.00M | 1304.00M | 22000.00M |
| Breakdown | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
| Investments | -41371.00000M | -11201.00000M | 4110.00M | -4923.00000M | -7727.00000M |
| Change to liabilities | - | 4412.00M | 2861.00M | 1576.00M | 398.00M |
| Total cashflows from investing activities | -41373.00000M | -26387.00000M | -22660.00000M | -4923.00000M | -7727.00000M |
| Net borrowings | - | 2735.00M | 6094.00M | -19165.00000M | -15182.00000M |
| Total cash from financing activities | -26861.00000M | -2422.00000M | -298.00000M | -25159.00000M | -21326.00000M |
| Change to operating activities | - | 4014.00M | -3349.00000M | 4821.00M | 4122.00M |
| Net income | 60485.00M | 23568.00M | 19149.00M | 19498.00M | 18795.00M |
| Change in cash | -9073.00000M | 32.00M | 12858.00M | -266.00000M | -314.00000M |
| Begin period cash flow | 14852.00M | 14820.00M | 1962.00M | 2228.00M | 2542.00M |
| End period cash flow | 5779.00M | 14852.00M | 14820.00M | 1962.00M | 2228.00M |
| Total cash from operating activities | 58873.00M | 28108.00M | 35703.00M | 29841.00M | 28704.00M |
| Issuance of capital stock | 368.00M | 334.00M | 269.00M | 4.00M | 0.00000M |
| Depreciation | 12502.00M | 11824.00M | 12796.00M | 12472.00M | 12190.00M |
| Other cashflows from investing activities | -30050.00000M | 873.00M | 1220.00M | 1016.00M | 781.00M |
| Dividends paid | 4979.00M | 4146.00M | 4147.00M | 3916.00M | 4002.00M |
| Change to inventory | -2654.00000M | -5328.00000M | -9881.00000M | -1487.00000M | -8496.00000M |
| Change to account receivables | - | -17012.00000M | 2081.00M | -12446.00000M | 6.00M |
| Sale purchase of stock | 368.00M | 334.00M | -1193.00000M | -474.00000M | -535.00000M |
| Other cashflows from financing activities | -21235.00000M | 2175.00M | 9270.00M | 2627.00M | -16789.00000M |
| Change to netincome | - | 6630.00M | 12046.00M | 5407.00M | -4118.00000M |
| Capital expenditures | 18864.00M | 19049.00M | 12561.00M | 6115.00M | 7491.00M |
| Change receivables | - | - | - | - | 0.00000M |
| Cash flows other operating | - | - | - | - | 0.00000M |
| Exchange rate changes | - | - | - | - | 0.00000M |
| Cash and cash equivalents changes | - | - | - | - | 0.00000M |
| Change in working capital | -7855.00000M | -13914.00000M | -8288.00000M | -7536.00000M | -5771.00000M |
| Stock based compensation | 397.00M | 592.00M | 584.00M | 521.00M | 389.00M |
| Other non cash items | -21956.00000M | -2692.00000M | 2287.00M | 6352.00M | -547.00000M |
| Free cash flow | 40009.00M | 9059.00M | 23142.00M | 23726.00M | 21213.00M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| RDY Dr. Reddy’s Laboratories Ltd ADR |
0.01 0.11% | 13.26 | 18.30 | 18.32 | 0.04 | 3.63 | 0.04 | 0.13 |
| ZTS Zoetis Inc |
-0.08 0.10% | 79.44 | 40.18 | 30.96 | 10.67 | 17.60 | 11.27 | 26.18 |
| MKKGY Merck KGaA ADR |
-1.13 3.48% | 31.32 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
-5.4 3.30% | 158.31 | 21.73 | 14.95 | 3.16 | 2.15 | 3.56 | 12.82 |
| GALDY GALDERMA GROUP AG |
-0.13 0.32% | 40.45 | 74.21 | 41.67 | 8.64 | 5.55 | 9.15 | 42.22 |
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
8-2-337, Road No. 3, Hyderabad, India, 500034
| Name | Title | Year Born |
|---|---|---|
| Mr. Gunupati Venkateswara Prasad B.E. | Co-Chairman, MD & Member of Management Council | 1960 |
| Mr. Kallam Satish Reddy B.Tech., M.S. | Chairman & Member of the Management Council | 1967 |
| Mr. Erez Israeli M.B.A. | CEO & Member of the Management Council | 1968 |
| Mr. Parag Agarwal | CFO & Member of Management Council | 1966 |
| Mr. Deepak Sapra M.B.A. | CEO of API & Services & Member of Management Council | 1975 |
| Mr. Venkata Ramana Motupalli M.B.A., MBA | CEO of Branded Markets - India & Emerging Countries and Member of Management Council | 1969 |
| Ms. Archana Bhaskar B.Sc., M.B.A. | EVP, Head of Corp. Communications, Chief HR Officer & Member of Management Council | 1967 |
| Mr. Sanjay Sharma B.Tech. | Exec. VP, Global Head of Global Manufacturing & Member of Management Council | 1968 |
| Mr. Marc Kikuchi B.A., M.B.A. | CEO of North America Generics & Member of Management Council | 1969 |
| Mr. Patrick Aghanian B.A., M.B.A. | CEO of European Generics & Member of Management Council | 1965 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...